Subhash Banerjee1, Karan Sarode2, Atif Mohammad2, Osvaldo Gigliotti2, Mirza S Baig2, Shirling Tsai2, Nicolas W Shammas2, Anand Prasad2, Mazen Abu-Fadel2, Andrew Klein2, Ehrin J Armstrong2, Haekyung Jeon-Slaughter2, Emmanouil S Brilakis2, Deepak L Bhatt2. 1. From the Veteran Affairs North Texas Healthcare System, Dallas (S.B., K.S., A.M., M.S.B., S.T., H.J.-S., E.S.B.); Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (S.B., A.M., M.S.B., S.T., H.J.-S., E.S.B.); Seton Medical Center, Austin, TX (O.G.); Midwest Cardiovascular Research Foundation, Davenport, IA (N.W.S.); Department of Medicine, Division of Cardiology, University of Texas Health Science Center, San Antonio (A.P.); Department of Internal Medicine, University of Oklahoma Medical Center (M.A.-F.); John Cochran Veteran Affairs Medical Center, St. Louis, MO (A.K.); Eastern Colorado Veteran Affairs Healthcare System, Denver (E.J.A.); and Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.). subhash.banerjee@va.gov. 2. From the Veteran Affairs North Texas Healthcare System, Dallas (S.B., K.S., A.M., M.S.B., S.T., H.J.-S., E.S.B.); Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (S.B., A.M., M.S.B., S.T., H.J.-S., E.S.B.); Seton Medical Center, Austin, TX (O.G.); Midwest Cardiovascular Research Foundation, Davenport, IA (N.W.S.); Department of Medicine, Division of Cardiology, University of Texas Health Science Center, San Antonio (A.P.); Department of Internal Medicine, University of Oklahoma Medical Center (M.A.-F.); John Cochran Veteran Affairs Medical Center, St. Louis, MO (A.K.); Eastern Colorado Veteran Affairs Healthcare System, Denver (E.J.A.); and Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).
Abstract
BACKGROUND: There are limited data on femoropopliteal artery stent thrombosis (ST), which is a serious adverse outcome of peripheral artery interventions. METHODS AND RESULTS: Index procedures resulting in femoropopliteal ST were compared with stent procedures without subsequent ST in the Excellence in Peripheral Artery Disease registry. The study data had a total of 724 cases of stent procedures and 604 unique patients. Femoropopliteal ST occurred in 26 of 604 patients (4.3%) over a median follow-up of 6 months post procedure. ST was more likely to occur in men (96.3% versus 82.2%; P=0.026) and to have an initial intervention for chronic total occlusions (88.5% versus 64.0%; P=0.01). There was no significant difference in ST between drug-coated and bare-metal stents (4.4% versus 3.4%; P=0.55), but the rate of ST was significantly higher with self-expanding covered stent grafts compared with bare-metal stents (10.6% versus 3.4%; P=0.02). ST was significantly associated with an increased risk of 12-month major adverse limb events (hazard ratio, 4.99; 95% confidence interval, 2.31-10.77; P<0.001) compared with no ST. On multivariate analysis, treatment of chronic total occlusion lesions (odds ratio, 3.46; 95% confidence interval, 0.98-12.20; P=0.05) and in-stent restenosis lesions (odds ratio, 5.30; 95% confidence interval, 1.83-15.32; P=0.002) were independently associated with an increased risk of ST. CONCLUSIONS: In a multicenter peripheral interventional registry, femoropopliteal ST occurred in 4.3% of patients who underwent stent procedures, and it was associated with treatment of chronic total occlusions and in-stent restenosis lesions, and had higher 12-month major adverse limb events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01904851.
BACKGROUND: There are limited data on femoropopliteal artery stent thrombosis (ST), which is a serious adverse outcome of peripheral artery interventions. METHODS AND RESULTS: Index procedures resulting in femoropopliteal ST were compared with stent procedures without subsequent ST in the Excellence in Peripheral Artery Disease registry. The study data had a total of 724 cases of stent procedures and 604 unique patients. Femoropopliteal ST occurred in 26 of 604 patients (4.3%) over a median follow-up of 6 months post procedure. ST was more likely to occur in men (96.3% versus 82.2%; P=0.026) and to have an initial intervention for chronic total occlusions (88.5% versus 64.0%; P=0.01). There was no significant difference in ST between drug-coated and bare-metal stents (4.4% versus 3.4%; P=0.55), but the rate of ST was significantly higher with self-expanding covered stent grafts compared with bare-metal stents (10.6% versus 3.4%; P=0.02). ST was significantly associated with an increased risk of 12-month major adverse limb events (hazard ratio, 4.99; 95% confidence interval, 2.31-10.77; P<0.001) compared with no ST. On multivariate analysis, treatment of chronic total occlusion lesions (odds ratio, 3.46; 95% confidence interval, 0.98-12.20; P=0.05) and in-stent restenosis lesions (odds ratio, 5.30; 95% confidence interval, 1.83-15.32; P=0.002) were independently associated with an increased risk of ST. CONCLUSIONS: In a multicenter peripheral interventional registry, femoropopliteal ST occurred in 4.3% of patients who underwent stent procedures, and it was associated with treatment of chronic total occlusions and in-stent restenosis lesions, and had higher 12-month major adverse limb events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01904851.
Authors: Leslie Cho; Marco Roffi; Debabrata Mukherjee; Deepak L Bhatt; Christopher Bajzer; Jay S Yadav Journal: J Invasive Cardiol Date: 2003-04 Impact factor: 2.022
Authors: D I Axel; W Kunert; C Göggelmann; M Oberhoff; C Herdeg; A Küttner; D H Wild; B R Brehm; R Riessen; G Köveker; K R Karsch Journal: Circulation Date: 1997-07-15 Impact factor: 29.690
Authors: Martin Schillinger; Schila Sabeti; Christian Loewe; Petra Dick; Jasmin Amighi; Wolfgang Mlekusch; Oliver Schlager; Manfred Cejna; Johannes Lammer; Erich Minar Journal: N Engl J Med Date: 2006-05-04 Impact factor: 91.245
Authors: A W Heldman; L Cheng; G M Jenkins; P F Heller; D W Kim; M Ware; C Nater; R H Hruban; B Rezai; B S Abella; K E Bunge; J L Kinsella; S J Sollott; E G Lakatta; J A Brinker; W L Hunter; J P Froehlich Journal: Circulation Date: 2001-05-08 Impact factor: 29.690
Authors: Peter A Schneider; John R Laird; Gunnar Tepe; Marianne Brodmann; Thomas Zeller; Dierk Scheinert; Christopher Metzger; Antonio Micari; Ravish Sachar; Michael R Jaff; Hong Wang; Melissa S Hasenbank; Prakash Krishnan Journal: Circ Cardiovasc Interv Date: 2018-01 Impact factor: 6.546